15/9/2017 4:23:00PM 15/9/2017 4:26:06PM 20/9/2017 4:58:24PM A/c Status. Test Name Results Units Bio. Ref. Interval < >40.00 mg/dl <150.

Transcription

1 Lab No Age 30 Years Gender Male 15/9/ M 15/9/ M 20/9/ M Ref By UNKNWON Final Test Results Units Bio Ref Interval SWASTH LUS HEALTH ADVANCE ANEL LIID ROFILE, BASIC, SERUM (Spectrophotometry, Calculated) Cholesterol Total <20000 Triglycerides <15000 HDL Cholesterol 4000 >4000 LDL Cholesterol <10000 VLDL Cholesterol 1000 <3000 Non-HDL Cholesterol <13000 Interpretation NATIONAL LIID TOTAL TRIGLYCERIDE LDL CHOLESTEROL NON HDL ASSOCIATION CHOLESTEROL in in CHOLESTEROL RECOMMENDATIONS in in (NLA-2014) Optimal <200 <150 <100 <130 Above Optimal Borderline High High >= Very High - >=500 >=190 >= Note 1 Measurements in the same patient can show physiological& analytical variations Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol 2 As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended 3 Low HDL levels are associated with increased risk foratherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues 4 NLA-2014identifies Non HDL Cholesterol(an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants)along with LDL-cholesterol as co- primary target for cholesterol lowering therapy Note that major risk factors can modify treatment goals for LDL &Non HDL 5 Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have been achieved atientreportscsuperanelgeneral_anel_analyte_sc (Version 6) age 1 of 8

2 Lab No Age 30 Years Gender Male 15/9/ M 15/9/ M 20/9/ M Ref By UNKNWON Final Test Results Units Bio Ref Interval 6 Additional testing for Apolipoprotein B, hscr,lp(a ) & L-LA2 should be considered among patients with moderate risk for ASCVD for risk refinement Treatment Goals as per NLA RISK CATEGORY NON HDL CHLOESTEROL LDL CHOLESTEROL AOLIOROTEIN B () (NON HDL-C) () (LDL-C)() Low/Moderate/High <130 <100 < Very High <100 <70 < LIVER & KIDNEY ANEL, SERUM (Spectrophotometry, Indirect ISE) Bilirubin Total Bilirubin Direct 010 <020 Bilirubin Indirect 040 <110 AST (SGOT) 20 U/L <50 ALT (SGT) 10 U/L <50 GGT 40 U/L <55 Alkaline hosphatase (AL) 115 U/L Total rotein 700 g/dl Albumin 400 g/dl A G Ratio Urea Creatinine Uric Acid Calcium, Total hosphorus Sodium meq/l otassium 500 meq/l Chloride meq/l THYROID ROFILE,TOTAL, SERUM (CLIA) T3, Total 100 ng/ml T4, Total 890 ug/dl TSH 260 uiu/ml atientreportscsuperanelgeneral_anel_analyte_sc (Version 6) age 2 of 8

3 Lab No Age 30 Years Gender Male 15/9/ M 15/9/ M 20/9/ M Ref By UNKNWON Final Test Results Units Bio Ref Interval Note 1 TSH levels are subject to circadian variation, reaching peak levels between 2-4am and at a minimum between 6-10 pm The variation is of the order of 50, hence time of the day has influence on the measured serum TSH concentrations 2 Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active 3 hysiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy Clinical Use rimary Hypothyroidism Hyperthyroidism Hypothalamic - ituitary hypothyroidism Inappropriate TSH secretion Nonthyroidal illness Autoimmune thyroid disease regnancy associated thyroid disorders Thyroid dysfunction in infancy and early childhood atientreportscsuperanelgeneral_anel_analyte_sc (Version 6) age 3 of 8

4 Lab No Age 30 Years Gender Male 15/9/ M 15/9/ M 20/9/ M Ref By UNKNWON Final Test Results Units Bio Ref Interval URINE EXAMINATION, ROUTINE; URINE, R/E (Automated Strip Test, Microscopy) hysical Colour Lemon Yellow ale yellow Specific Gravity ph Chemical roteins Glucose Ketones Bilirubin Urobilinogen Leucocyte Esterase Nitrite Microscopy Normal Normal RBC us Cells Epithelial Cells Casts Crystals Others WBC / hpf Few /lpf atientreportscsuperanelurine_examination_sc (Version 6) age 4 of 8

5 Lab No Age 30 Years Gender Male 15/9/ M 15/9/ M 20/9/ M Ref By UNKNWON Final Test Results Units Bio Ref Interval HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD (HLC, NGS certified) 51 Interpretation As per American Diabetes Association (ADA) Reference Group HbA1c in Non diabetic adults >=18 years < At risk (rediabetes) Diagnosing Diabetes >= Therapeutic goals for glycemic Age > 19 years control Goal of therapy < 70 Action suggested > 80 Age < 19 years Goal of therapy < Note 1 Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c Converse is true for a diabetic previously under good control but now poorly controlled 2 Target goals of < 70 may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 70 may not be appropriate Comments HbA1c provides an index of average blood glucose levels over the past 8-12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations ADA criteria for correlation between HbA1c & Mean plasma glucose levels HbA1c() Mean lasma Glucose () atientreportscsuperanelhbelectro_sc (Version 7) age 5 of 8

6 Lab No Age 30 Years Gender Male 15/9/ M 15/9/ M 20/9/ M Ref By UNKNWON Final Test Results Units Bio Ref Interval atientreportscsuperanelhbelectro_sc (Version 7) age 6 of 8

7 Lab No Age 30 Years Gender Male 15/9/ M 15/9/ M 20/9/ M Ref By UNKNWON Final Test Results Units Bio Ref Interval HEMOGRAM (Electrical Impendance & VCS, Capillary photometry,hotometry) Hemoglobin 1130 g/dl acked Cell Volume (CV) RBC Count 416 mill/mm MCV 8370 fl MCH 2710 pg MCHC 3240 g/dl Red Cell Distribution Width (RDW) Total Leukocyte Count (TLC) Differential Leucocyte Count (DLC) Segmented Neutrophils 6540 Lymphocytes 2360 Monocytes 830 Eosinophils 200 Basophils 070 Absolute Leucocyte Count <200 Neutrophils Lymphocytes Monocytes Eosinophils Basophils latelet Count ESR 18 mm/hr 0-15 Note 1 As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of blood 2 Test conducted on EDTA whole blood age 7 of 8

8 Lab No Age 30 Years Gender Male 15/9/ M 15/9/ M 20/9/ M Ref By UNKNWON Final Test Results Units Bio Ref Interval GLUCOSE, FASTING (F), LASMA (Hexokinase) C-REACTIVE ROTEIN; CR, SERUM (Immunoturbidimetry) Comments mg/l <500 CR is an acute phase reactant which is used in inflammatory disorders for monitoring course and effect of therapy It is most useful as an indicator of activity in Rheumatoid arthritis, Rheumatic fever, tissue injury or necrosis and infections As compared to ESR, CR shows an earlier rise in inflammatory disorders which begins in 4-6 hrs, the intensity of the rise being higher than ESR and the recovery being earlier than ESR Unlike ESR, CR levels are not influenced by hematologic conditions like Anemia, olycythemia etc Dr Anil Arora MD (athology) HOD Hemat & Imm Dr Biswadip Hazarika MD (athology) Sr Consultant athologist Dr Himangshu Mazumdar MD (Biochemistry) Consultant Biochemist Dr Nimmi Kansal MD (Biochemistry) HOD Biochem & IA Dr Shalabh Malik MD (Microbiology) National Head - Microbiology & Serology End of report atientreportscsuperanels_general_temlate01_sc (Version 7) age 8 of 8